Miscellaneous (Wiki)

Miscellaneous medications that possess tranquilising effects.


Etafenoxine/Etifoxine (Wiki)

Brand names: None known
Formula: C17H17ClN2O
Half life: Unknown
Single unit dose: Unknown
Recommended outpatient dose: 150mg to 200mg per day [Verified]
Maximum outpatient dose: Unknown

Etafenoxine is a tranquilising and anticonvulsant drug and has similar functions to that of Benzodiazepines but is structurally dissimilar. It is a more effective then Lorazepam as an anxiolytic but exhibits fewer typical side effects. Unlike Benzodiazepines, the drug is not reversed by the presence of Flumazenil.

L-838,417 (Wiki)

Brand names: None known
Formula: C19H19F2N7O
Half life: Unknown
Single unit dose: Unknown
Recommended outpatient dose: Unknown
Maximum outpatient dose: Unknown

L-838-471 is an anxiolytic drug used in research. It is classed as a Nonbenzodiazepine as, although it exhibits similar effects to that of a Benzodiazepine, it is structurally unrelated. The compound was developed by Merck, Sharp and Dohme. Although primarily a tranquiliser, some sedation is to be expected.

Panadiplon/U-78875 (Wiki)

Brand names: None known
Formula: C18H17N5O2
Half life: Unknown
Single unit dose: Unknown
Recommended outpatient dose: Unknown
Maximum outpatient dose: Unknown

A novel tranquilising drug with a novel structure, Panadiplon posses very little in the way of sedative properties. Sadly, the drug was discontinued in research after it was discovered that it caused liver damage in test subjects.

RWJ-51204 (Wiki)

Brand names: None known
Formula: C21H19F2N3O3
Half life: Unknown
Single unit dose: Unknown
Recommended outpatient dose: Unknown
Maximum outpatient dose: Unknown

A novel anxiolytic drug with similar actions to that of Benzodiazepines, this medication has been discontinued at time of writing.

Y-23684 (Wiki)

Brand names: None known
Formula: C18H13ClN2O2S
Half life: Unknown
Single unit dose: Unknown
Recommended outpatient dose: Unknown
Maximum outpatient dose: Unknown

Although it has not entered animal testing phase, this drug exhibits tranquilising effects as well as, at higher doses, sedative and muscle relaxing properties.